Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

@article{Cheng2015MemorialSK,
  title={Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.},
  author={Donavan T. Cheng and Talia N Mitchell and Ahmet Zehir and Ronak H Shah and Ryma Benayed and Aijazuddin Syed and Raghu Chandramohan and Zhen Yu Liu and Helen H. Won and Sasinya N. Scott and Angela Rose Brannon and Catherine O'Reilly and Justyna Sadowska and Jacklyn Casanova and Angela Yannes and Jaclyn Frances Hechtman and Jinjuan Yao and Wei Song and Dara S. Ross and Alifya Oultache and Snjezana Dogan and Laetitia Borsu and Meera R. Hameed and Kh{\'e}doudja Nafa and Maria E. Arcila and Marc Ladanyi and Michael F. Berger},
  journal={The Journal of molecular diagnostics : JMD},
  year={2015},
  volume={17 3},
  pages={251-64}
}
The identification of specific genetic alterations as key oncogenic drivers and the development of targeted therapies are together transforming clinical oncology and creating a pressing need for increased breadth and throughput of clinical genotyping. Next-generation sequencing assays allow the efficient and unbiased detection of clinically actionable mutations. To enable precision oncology in patients with solid tumors, we developed Memorial Sloan Kettering-Integrated Mutation Profiling of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 15 times over the past 90 days. VIEW TWEETS
184 Citations
41 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 184 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Similar Papers

Loading similar papers…